Pain Relief Effect of Low-intensity Continuous Ultrasound Stimulator for Knee Arthritis
Launched by KYU JAE LEE · Dec 15, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
Subject: 35 osteoarthritis patients Evaluation measure: Visual Analogue Scale (VAS), McMaster Universities Osteoarthritis Index (WOMAC) Method: A total of 35 subjects were selected in consideration of the dropout rate of 20%. Selected subjects were treated as a single group without randomization, and an appropriate amount of gel was applied to the knee OA pain area for 4 weeks. A blinded evaluation at baseline and after treat-ment was made. Primary outcome was pain on movement assessed by the VAS index. Secondary outcomes consisted of the WOMAC scores.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 40 to 60 years with pain due to OA of the knee and able to walk voluntarily
- • Those who have more than one osteophyte in the tibiofemoral joint on radiographic findings (Kellgren-Lawrence gradesⅡ,Ⅲ)
- • At visit 1 (screening) and visit 2, the pain status during knee OA activity was 100 mm pain VAS, as a result, those who are over 40mm
- • If the Kellgren \& Lawrence Grades are the same, target the one with the higher 100mm pain VAS
- • Patients who are willing or able to follow the doctor's instructions, including joint movements
- • Persons who can comply with concomitantly permitted drugs, prohibited drugs, and relief drugs
- • Persons who can maintain the same exercise and activity during the clinical trial period
- • Fully understand the purpose and procedure of this clinical trial
- Exclusion Criteria:
- • Those who have a history of rheumatoid arthritis or gouty arthritis or who have peripheral pain other than the knee joint patient.
- • Those with fractures or dislocations on simple radiological examination.
- • Those who are identified, or those with a similar risk of neuromuscular disease
- • Those who have participated in other clinical trials within 6 months of participating in clinical trials.
- • Patients with severe pain in the knee joint other than angular deformity, instability, and index knee in the knee joint
- • Patients with other tumors other than degenerative knee arthrosis
- • Persons with systemic symptoms that may affect knee pain
- • Pregnant and lactating women
Trial Officials
Kyu-Jae Lee, Ph.D.
Principal Investigator
Department of Convergence Medicine, Wonju College of Medicine, Yonsei University
About Kyu Jae Lee
Kyu Jae Lee is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial designs and rigorous methodologies. With a focus on developing effective therapeutic solutions, Kyu Jae Lee collaborates with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of ethical conduct and scientific integrity in clinical investigations. By leveraging a wealth of expertise and a patient-centered approach, Kyu Jae Lee aims to contribute significantly to the field of medicine and enhance the quality of life for individuals globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wonju, Ganwon Do, Korea, Republic Of
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials